Skip to main navigation Skip to search Skip to main content

A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer

  • Seyoung Seo
  • , Bhumsuk Keam
  • , Seong Hoon Shin
  • , Yee Soo Chae
  • , Tae Min Kim
  • , Lee Chun Park
  • , Seung Beom Hong
  • , Myung Ju Ahn
  • , Sung Bae Kim
  • University of Ulsan
  • Seoul National University
  • Kosin University
  • Kyungpook National University
  • Ltd.

Research output: Contribution to journal › Article › peer-review

5   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science